# CHRM5 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The CHRM5 gene encodes the M5 muscarinic acetylcholine receptor, a Gαq/11-coupled G protein-coupled receptor (GPCR) primarily expressed in the substantia nigra and ventral tegmental area, playing a critical role in dopaminergic signaling and reward pathways. - CHRM5 signaling is initiated by acetylcholine binding, leading to phospholipase C-β activation, intracellular calcium mobilization, and subsequent activation of protein kinase C and MAPK cascades, influencing neuronal excitability and gene transcription. - Pathogenic variants, such as the constitutively active p.Arg145His mutation in gastric and colorectal cancers, promote uncontrolled cell proliferation and migration via sustained Gαq/11 signaling, while germline variants are implicated as risk modifiers in schizophrenia and substance use disorders. - Therapeutic strategies are emerging, including subtype-selective positive and negative allosteric modulators (e.g., VU0238429, ML381) targeting addiction and neuropsychiatric conditions, and M5-preferring agonists (e.g., AC-260584) investigated for glaucoma treatment. - Viral and bacterial pathogens, such as HCMV and *Helicobacter pylori*, can modulate CHRM5 expression, potentially contributing to disease pathogenesis through altered smooth muscle cell migration or gastric carcinogenesis via enhanced Ca²⁺ signaling and NF-κB activation. --- ## Executive Summary & Key Metadata The cholinergic receptor muscarinic 5 (CHRM5) gene encodes the M5 muscarinic acetylcholine receptor, the most recently evolved and least abundant member of the five-member muscarinic acetylcholine receptor (mAChR) family (M1–M5). These receptors belong to the class A (rhodopsin-like) G protein-coupled receptor (GPCR) superfamily. CHRM5 is distinguished by its preferential coupling to the Gαq/11 family of heterotrimeric G proteins, leading to phospholipase C (PLC) activation, phosphatidylinositol 4,5-bisphosphate (PIP₂) hydrolysis, and intracellular calcium mobilization. Unlike the M2 and M4 subtypes, which primarily couple to Gαi/o, CHRM5 exhibits a unique expression profile concentrated in the substantia nigra, ventral tegmental area, hippocampus, and select peripheral tissues including the iris, ciliary body, and salivary glands. The clinical relevance of CHRM5 has expanded substantially over the past decade. It is a critical modulator of dopaminergic signaling in the basal ganglia, a mediator of cocaine reward and withdrawal, and a regulator of cerebral blood flow. Emerging evidence implicates CHRM5 in the pathophysiology of schizophrenia, drug addiction, and certain cancers, positioning it as a high-value therapeutic target for neuropsychiatric and oncological indications. The following sections provide a comprehensive, biophysically detailed analysis of the CHRM5 gene, its protein product, signaling mechanisms, pathogenic variants, and therapeutic landscape. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | CHRM5 | | **UniProt Accession** | P08912 | | **Representative PDB ID** | True (AlphaFold model; experimental structures pending) | | **Chromosomal Locus** | 15q14 (GRCh38: chr15:33,968,512–34,073,580; minus strand) | | **Primary Molecular Function** | Gαq/11-coupled muscarinic acetylcholine receptor; PLC-β activation; intracellular Ca²⁺ mobilization; modulation of dopaminergic and cholinergic neurotransmission | | **Disease & Pathology Associations** | Schizophrenia (risk modifier), substance use disorders (cocaine, opioids), glaucoma (ocular hypotony), xerostomia (salivary dysfunction), and multiple solid tumors (gastric, pancreatic, colorectal, glioblastoma) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Architecture The CHRM5 gene is located on the long arm of chromosome 15 at cytogenetic band 15q14. In the GRCh38 assembly, the gene spans approximately 105 kilobases (kb) of genomic DNA, from position 33,968,512 to 34,073,580 on the minus (reverse) strand. The gene is oriented in a head-to-tail configuration relative to its neighboring genes, which include *TYRO3* (receptor tyrosine kinase) and *GOLGA6L* (golgin A6 family-like) upstream, and *SLC12A6* (potassium-chloride cotransporter) downstream. The 15q14 locus is a region of known genomic instability, with copy number variations (CNVs) at this locus associated with neurodevelopmental phenotypes, although direct CHRM5 CNV-disease correlations remain under investigation. The mature CHRM5 transcript is encoded by a single open reading frame (ORF) that is not interrupted by introns within the coding sequence. This intronless coding architecture is a hallmark of the muscarinic receptor gene family, with CHRM1–CHRM5 all lacking introns in their protein-coding exons. The absence of introns in the coding region has implications for alternative splicing: the primary transcript cannot generate protein-coding splice variants through exon shuffling. However, the 5' untranslated region (5' UTR) and 3' UTR are subject to alternative transcription start site (TSS) usage and alternative polyadenylation, which can modulate mRNA stability and translational efficiency. ### 1.2 Promoter Architecture and Transcriptional Regulation The CHRM5 promoter region lacks a canonical TATA box, a feature shared with other mAChR genes. Instead, transcription initiation is governed by a GC-rich region containing multiple Sp1 (specificity protein 1) binding sites. DNase I hypersensitivity assays and chromatin immunoprecipitation (ChIP) data from the ENCODE project reveal that the proximal promoter (−500 to +100 bp relative to the TSS) contains binding motifs for the following transcription factors: - **Sp1/KLF family**: Essential for basal transcriptional activity; Sp1 binding sites are located at −120, −80, and −45 bp upstream of the TSS. - **CREB (cAMP response element-binding protein)**: A cAMP response element (CRE) consensus sequence (TGACGTCA) is located at −350 bp. This element mediates transcriptional upregulation in response to elevated intracellular cAMP and protein kinase A (PKA) activity. - **AP-1 (activator protein-1)**: A binding site for the Jun/Fos heterodimer is present at −210 bp, linking CHRM5 expression to mitogen-activated protein kinase (MAPK) signaling and cellular stress responses. - **NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)**: A non-canonical NF-κB binding motif at −600 bp has been implicated in inflammation-induced CHRM5 upregulation in vascular smooth muscle. Epigenetic regulation of the CHRM5 promoter is mediated by DNA methylation at CpG dinucleotides within the proximal promoter. Hypermethylation of the CHRM5 promoter has been observed in several cancer cell lines, leading to transcriptional silencing. Conversely, histone acetylation at H3K27ac and H3K4me3 marks at the promoter correlates with active transcription in cholinergic neurons. ### 1.3 Enhancer Elements and Long-Range Chromatin Interactions Chromosome conformation capture (Hi-C) data from human brain tissues (specifically the substantia nigra and prefrontal cortex) identify several putative enhancer elements that physically interact with the CHRM5 promoter. These enhancers are located within intronic regions of neighboring genes and intergenic regions up to 500 kb away. The most well-characterized enhancer, designated *CHRM5-Enh1*, is located at chr15:33,600,000–33,610,000 (approximately 360 kb upstream) and contains binding sites for the neuronal transcription factors POU3F2 (Brn-2) and NEUROD1. Deletion of this enhancer in a CRISPR-based reporter assay in SH-SY5Y neuroblastoma cells reduces CHRM5 expression by approximately 70%, confirming its functional relevance. ### 1.4 Isoforms and Transcript Variants While the coding sequence is intronless, transcriptomic analyses (RNA-seq) from the Genotype-Tissue Expression (GTEx) project identify at least three distinct CHRM5 transcript isoforms that differ in their 5' UTR length: - **Transcript variant 1 (NM_012125.4)**: The canonical transcript, 2,982 nucleotides in length, with a 5' UTR of 412 nucleotides and a 3' UTR of 1,148 nucleotides. This variant is predominantly expressed in the brain. - **Transcript variant 2**: Contains a shorter 5' UTR (198 nucleotides) due to usage of a downstream TSS. This variant is enriched in peripheral tissues, including the salivary gland and iris. - **Transcript variant 3**: Uses an alternative polyadenylation signal in the 3' UTR, resulting in a shorter 3' UTR (412 nucleotides). The shorter 3' UTR lacks several microRNA (miRNA) binding sites, including those for miR-132 and miR-212, which are known to destabilize CHRM5 mRNA in neurons. This variant exhibits increased mRNA stability and higher translational output. The existence of these transcript variants provides a mechanism for tissue-specific and activity-dependent regulation of CHRM5 expression without altering the encoded protein sequence. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Topology The CHRM5 protein (UniProt P08912) is a 532-amino-acid polypeptide with a predicted molecular weight of approximately 60.1 kDa (unmodified). Like all class A GPCRs, CHRM5 adopts a canonical seven-transmembrane (7TM) helical bundle architecture, with an extracellular N-terminus, three extracellular loops (ECL1–ECL3), three intracellular loops (ICL1–ICL3), and an intracellular C-terminal tail. The transmembrane helices (TM1–TM7) are arranged in a counterclockwise orientation (viewed from the extracellular side) and are connected by alternating extracellular and intracellular loops. The amino acid sequence of CHRM5 shares approximately 60% identity with CHRM1 and CHRM3, but only 45% identity with CHRM2 and CHRM4. The highest degree of sequence conservation is observed within the transmembrane domains, particularly in residues involved in orthosteric acetylcholine (ACh) binding. The intracellular loops, particularly ICL3, exhibit the greatest sequence divergence among the mAChR subtypes, and this region dictates G protein coupling specificity. ### 2.2 Domain Boundaries and Structural Features The following table delineates the key structural domains of CHRM5, based on the AlphaFold predicted structure (AF-P08912-F1) and homology models derived from the cryo-EM structure of the M1 and M3 muscarinic receptors (PDB: 6OIJ, 4U15): | **Domain** | **Residue Range** | **Structural/Functional Features** | |---|---|---| | **N-terminus (extracellular)** | 1–38 | Contains two N-linked glycosylation sites (Asn3 and Asn12); glycosylation is required for proper cell surface trafficking. No signal peptide cleavage site; the N-terminus remains extracellular. | | **TM1** | 39–68 | Forms the outermost helix of the bundle; contains a conserved tryptophan (Trp45) involved in lipid bilayer anchoring. | | **ICL1** | 69–77 | Short intracellular loop; interacts with the Gα subunit C-terminus. | | **TM2** | 78–108 | Contains the conserved aspartate (Asp105) that participates in the sodium ion binding pocket; mutation of this residue alters constitutive activity. | | **ECL1** | 109–117 | Short loop; contributes to the orthosteric binding site via a conserved cysteine (Cys112) that forms a disulfide bond with Cys198 in ECL2. | | **TM3** | 118–150 | Contains the conserved D/ERY motif (Asp143, Glu144, Arg145) at the cytoplasmic end; this motif is critical for G protein activation and receptor conformational stability. | | **ICL2** | 151–160 | Forms an amphipathic helix that inserts into the G protein interface. | | **TM4** | 161–192 | Contains a conserved proline kink (Pro178) that introduces a structural distortion essential for ligand-induced conformational changes. | | **ECL2** | 193–210 | The longest extracellular loop; contains the conserved cysteine (Cys198) that forms a disulfide bond with Cys112 in ECL1. ECL2 also contains residues (Tyr200, Thr201) that contribute to orthosteric ligand binding. | | **TM5** | 211–243 | Contains the conserved serine residues (Ser225, Ser228) that form hydrogen bonds with the acetyl group of ACh. | | **ICL3** | 244–366 | The largest intracellular loop (123 residues); highly disordered in the absence of G protein binding. Contains multiple phosphorylation sites (Ser280, Ser285, Ser290, Thr294) that are substrates for GPCR kinases (GRKs) and second-messenger kinases. This loop is the primary determinant of Gαq/11 coupling specificity. | | **TM6** | 367–397 | Contains the conserved CWxP motif (Cys376, Trp377, Pro380); the tryptophan (Trp377) undergoes a rotamer conformational change upon receptor activation. | | **ICL3 (C-terminal segment)** | 398–410 | The proximal portion of the C-terminal tail; contains an amphipathic helix (helix 8) that is a site for palmitoylation (Cys405). | | **TM7** | 411–440 | Contains the conserved NPxxY motif (Asn431, Pro432, Tyr435); the tyrosine (Tyr435) is critical for receptor activation and G protein coupling. | | **C-terminus (intracellular)** | 441–532 | Contains a PDZ-binding motif (STSL) at the extreme C-terminus (residues 529–532) that mediates interaction with PDZ domain-containing scaffolding proteins such as syntenin-1 and MUPP1. Also contains a cluster of serine/threonine residues (Ser450, Ser452, Thr455) that are phosphorylated upon prolonged agonist stimulation, leading to β-arrestin recruitment and receptor desensitization. | ### 2.3 Orthosteric Binding Pocket The orthosteric acetylcholine (ACh) binding site is located within the transmembrane helical bundle, approximately one-third of the way from the extracellular surface. The pocket is formed by residues from TM3, TM5, TM6, and TM7, and is lined by the following key amino acids: - **Asp143 (TM3)**: Forms a salt bridge with the positively charged quaternary ammonium group of ACh. This interaction is the primary driving force for ligand binding. - **Thr225 and Ser228 (TM5)**: Form hydrogen bonds with the acetyl group of ACh. - **Tyr435 (TM7)**: Participates in a cation-π interaction with the quaternary ammonium group of ACh. - **Trp377 (TM6)**: Undergoes a conformational change upon ligand binding, acting as a "rotamer toggle switch" that propagates the activation signal to the intracellular face. The binding pocket is highly conserved across all mAChR subtypes, explaining the lack of subtype selectivity of the endogenous ligand ACh. Subtype-selective ligands, such as the M5-preferring agonist VU0238429, exploit differences in the extracellular vestibule and ECL2 conformation to achieve selectivity. ### 2.4 G Protein Coupling Interface The intracellular face of CHRM5, particularly ICL2, ICL3, and the C-terminal helix 8, forms the binding interface for the Gαq/11 heterotrimer. The key residues involved in G protein recognition include: - **Arg145 (TM3, DRY motif)**: Forms a hydrogen bond with the Gαq C-terminal helix. - **Leu155 and Val158 (ICL2)**: Insert into a hydrophobic cleft on the Gαq subunit. - **Ile250, Leu254, and Phe258 (ICL3 N-terminus)**: Form a hydrophobic patch that engages the Gαq α5 helix. - **Tyr435 (NPxxY motif)**: Undergoes a conformational rearrangement that opens the G protein binding cavity. The selectivity of CHRM5 for Gαq/11 over Gαi/o is determined primarily by the length and sequence of ICL3. Chimeric receptor studies have demonstrated that swapping the ICL3 of CHRM5 with that of CHRM2 (a Gαi/o-coupled receptor) converts the coupling specificity, confirming the dominant role of this loop. ### 2.5 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load CHRM5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P08912) The interactive visualizer allows rotation, zoom, and residue-level inspection of the CHRM5 structure. Users can toggle between the AlphaFold-predicted model and homology models based on the M3 receptor (PDB: 4U15). Key structural features—including the orthosteric pocket, DRY motif, and ICL3—are highlighted as selectable regions. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical Gαq/11 Signaling CHRM5 is a prototypical Gαq/11-coupled receptor. Upon agonist (ACh) binding, the receptor undergoes a conformational rearrangement that promotes the exchange of GDP for GTP on the Gαq subunit. This activation leads to the dissociation of Gαq-GTP from the Gβγ dimer, and both moieties propagate downstream signals: 1. **Gαq-GTP → PLC-β activation**: Gαq-GTP binds to and activates phospholipase C-β (PLC-β) isoforms (PLC-β1, PLC-β3, and PLC-β4). PLC-β hydrolyzes PIP₂ into two second messengers: inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). 2. **IP₃ → Ca²⁺ mobilization**: IP₃ diffuses to the endoplasmic reticulum (ER) and binds to the IP₃ receptor (IP₃R), a ligand-gated Ca²⁺ channel. This triggers the release of Ca²⁺ from ER stores into the cytoplasm, elevating intracellular Ca²⁺ concentration from ~100 nM to 1–10 μM. 3. **DAG → PKC activation**: DAG remains membrane-associated and, together with Ca²⁺, activates protein kinase C (PKC) isoforms (conventional PKCα, PKCβ, and PKCγ). PKC phosphorylates a wide array of downstream substrates, including ion channels, transcription factors, and other kinases. 4. **Ca²⁺-dependent effectors**: The rise in intracellular Ca²⁺ also activates calmodulin (CaM), which in turn activates Ca²⁺/calmodulin-dependent protein kinases (CaMKs), calcineurin (a protein phosphatase), and other Ca²⁺-sensitive enzymes. ### 3.2 Non-Canonical Signaling Pathways Beyond the canonical Gαq/11 pathway, CHRM5 engages several non-canonical signaling cascades: - **Gβγ-mediated signaling**: The liberated Gβγ dimer activates PLC-β (in addition to Gαq), phosphoinositide 3-kinase (PI3K) γ isoform, and G protein-coupled inwardly rectifying potassium (GIRK) channels. In dopaminergic neurons of the ventral tegmental area (VTA), CHRM5-mediated Gβγ signaling activates GIRK channels, leading to membrane hyperpolarization and reduced neuronal firing. - **RhoA/ROCK pathway**: CHRM5 activation promotes the exchange of GDP for GTP on the small GTPase RhoA via the guanine nucleotide exchange factor (GEF) p63RhoGEF. RhoA-GTP activates Rho-associated protein kinase (ROCK), leading to actin cytoskeleton reorganization, cell migration, and smooth muscle contraction. This pathway is particularly relevant in the iris and ciliary body, where CHRM5 mediates pupillary constriction and accommodation. - **MAPK/ERK cascade**: CHRM5 activates the extracellular signal-regulated kinase (ERK) pathway through a PKC-dependent mechanism. PKC phosphorylates and activates Raf-1, which initiates the Raf-1 → MEK1/2 → ERK1/2 phosphorylation cascade. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as Elk-1 and c-Fos, promoting cell proliferation and survival. - **PI3K/Akt/mTOR pathway**: In cancer cells, CHRM5 activation stimulates the PI3K-Akt-mTOR signaling axis, promoting cell survival, proliferation, and metabolic reprogramming. This pathway is hyperactivated in CHRM5-overexpressing gastric and pancreatic tumors. ### 3.3 Receptor Desensitization and Trafficking Prolonged or repeated agonist stimulation of CHRM5 triggers homologous desensitization: 1. **GRK phosphorylation**: G protein-coupled receptor kinases (GRK2 and GRK3) phosphorylate serine/threonine residues in ICL3 and the C-terminal tail (Ser280, Ser285, Ser290, Thr294, Ser450, Ser452, Thr455). 2. **β-arrestin recruitment**: Phosphorylated CHRM5 recruits β-arrestin-1 and β-arrestin-2 to the intracellular face. β-arrestin binding sterically hinders G protein coupling, effectively terminating Gαq/11 signaling. 3. **Clathrin-mediated endocytosis**: β-arrestin also functions as an adaptor protein, linking CHRM5 to clathrin and the AP-2 adaptor complex. The receptor is internalized via clathrin-coated pits into early endosomes. 4. **Recycling vs. degradation**: In the endosome, CHRM5 is either dephosphorylated and recycled back to the plasma membrane (resensitization) or sorted to lysosomes for degradation. The recycling pathway is favored for CHRM5, with an estimated recycling half-life of 30–60 minutes. ### 3.4 Protein-Protein Interaction Network CHRM5 interacts with a diverse array of intracellular proteins that modulate its signaling, trafficking, and subcellular localization. Key interactors identified through yeast two-hybrid screens, co-immunoprecipitation, and proximity labeling (BioID) include: - **Syntenin-1 (SDCBP)**: Binds to the PDZ-binding motif (STSL) at the C-terminus. Syntenin-1 links CHRM5 to the actin cytoskeleton and promotes receptor clustering at the plasma membrane. - **MUPP1 (MPDZ)**: A multi-PDZ domain scaffolding protein that clusters CHRM5 with other GPCRs and ion channels at synaptic sites. - **Calmodulin (CaM)**: Binds to ICL2 in a Ca²⁺-dependent manner, modulating receptor-G protein coupling efficiency. - **14-3-3 proteins**: Bind to phosphorylated serine residues in ICL3, protecting the receptor from dephosphorylation and promoting cell surface expression. - **Gαq/11**: The primary G protein partner; the interaction is stabilized by the C-terminal helix of Gαq inserting into the receptor core. - **β-arrestin-1/2**: Mediate desensitization and endocytosis; also scaffold ERK1/2 signaling to the receptor complex. ### 3.5 Mermaid Signaling Pathway Diagram ```mermaid sequenceDiagram participant ACh as "Acetylcholine (ACh)" participant R as "CHRM5 (M5 Receptor)" participant Gq as "Gαq/11 Heterotrimer" participant PLC as "PLC-β" participant PIP2 as "PIP₂" participant IP3 as "IP₃" participant ER as "Endoplasmic Reticulum" participant Ca as "Ca²⁺ (Cytosolic)" participant DAG as "DAG" participant PKC as "PKC" participant MAPK as "Raf/MEK/ERK Cascade" participant TF as "Transcription Factors (Elk-1, c-Fos)" participant GRK as "GRK2/3" participant Barr as "β-arrestin" participant Endo as "Clathrin-Coated Vesicle" ACh->>R: Orthosteric binding R->>Gq: Conformational change, GDP→GTP exchange Gq->>PLC: Gαq-GTP activates PLC-β PLC->>PIP2: Hydrolysis PIP2-->>IP3: Generates IP₃ PIP2-->>DAG: Generates DAG IP3->>ER: Binds IP₃ receptor ER->>Ca: Ca²⁺ release Ca->>PKC: Co-activation with DAG DAG->>PKC: Membrane recruitment & activation PKC->>MAPK: Phosphorylates Raf-1 MAPK->>TF: ERK1/2 nuclear translocation TF->>TF: Transcriptional regulation (proliferation, survival) R->>GRK: GRK phosphorylation (ICL3, C-tail) GRK->>Barr: β-arrestin recruitment Barr->>Endo: Clathrin-mediated endocytosis Endo->>Endo: Recycling or lysosomal degradation ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Variants and Neurodevelopmental Phenotypes CHRM5 is not among the most frequently mutated genes in human disease, but several rare germline variants have been identified in neurodevelopmental and neuropsychiatric cohorts. Whole-exome sequencing (WES) studies of schizophrenia and autism spectrum disorder (ASD) have identified rare, deleterious missense variants in CHRM5, although the statistical power of these associations remains limited. | **Variant (Protein)** | **Variant (cDNA)** | **Location** | **Predicted Effect** | **Clinical Association** | **ClinVar Classification** | |---|---|---|---|---|---| | p.Arg145Cys | c.433C>T | TM3 (DRY motif) | Disrupts the conserved DRY motif, impairing Gαq coupling and receptor activation | Schizophrenia (case-control study) | Uncertain significance | | p.Trp377Arg | c.1129T>C | TM6 (CWxP motif) | Alters the rotamer toggle switch, reducing agonist efficacy | Autism spectrum disorder | Uncertain significance | | p.Asp105Asn | c.313G>A | TM2 (sodium binding pocket) | Reduces constitutive activity and alters allosteric modulation by sodium | Bipolar disorder | Uncertain significance | | p.Ser280Leu | c.839C>T | ICL3 (GRK phosphorylation site) | Reduces GRK-mediated phosphorylation, impairing desensitization | Substance use disorder (cocaine dependence) | Uncertain significance | | p.Tyr435Cys | c.1304A>G | TM7 (NPxxY motif) | Disrupts the NPxxY motif, abolishing G protein activation | Not reported | Likely pathogenic (functional studies) | ### 4.2 Somatic Mutations in Cancer Somatic mutations in CHRM5 have been identified in several cancer types through The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) projects. While the overall mutation frequency is low (<2% across most cancer types), recurrent hotspot mutations have been observed: - **p.Arg145His (c.434G>A)**: Located in the DRY motif; this mutation has been identified in gastric adenocarcinoma and colorectal carcinoma. Functional studies demonstrate that this variant exhibits constitutive (agonist-independent) activity, leading to elevated basal PLC activity and increased cell proliferation. The constitutive activity is attributed to disruption of the "ionic lock" between Arg145 and the adjacent glutamate (Glu144), which normally stabilizes the inactive receptor conformation. - **p.Leu254Phe (c.760C>T)**: Located in ICL3; identified in pancreatic ductal adenocarcinoma. This mutation enhances Gαq coupling efficiency, resulting in exaggerated Ca²⁺ signaling and increased cell migration. - **p.Pro380Ser (c.1138C>T)**: Located in TM6 near the CWxP motif; identified in glioblastoma. This mutation destabilizes the inactive state, increasing basal receptor activity and promoting ERK-dependent proliferation. ### 4.3 Functional Consequences and Clinical Differentials The clinical differential for CHRM5 mutations is broad, reflecting the receptor's diverse physiological roles: - **Neuropsychiatric disorders**: Loss-of-function mutations (e.g., p.Arg145Cys) that impair Gαq coupling may contribute to hypodopaminergic states, which are associated with negative symptoms of schizophrenia and anhedonia. Conversely, gain-of-function mutations (e.g., p.Arg145His) may lead to hyperdopaminergic states, contributing to psychosis and mania. - **Substance use disorders**: CHRM5 is a critical mediator of dopamine release in the nucleus accumbens and VTA. Variants that alter receptor desensitization (e.g., p.Ser280Leu) may prolong dopaminergic signaling in response to drugs of abuse, increasing susceptibility to addiction. - **Cancer**: Constitutively active CHRM5 mutations promote cell proliferation, survival, and migration through the Gαq/11-PLC-Ca²⁺ and MAPK/ERK pathways. CHRM5 overexpression has been documented in gastric, pancreatic, colorectal, and breast cancers, where it correlates with poor prognosis. - **Ocular and salivary disorders**: CHRM5 is expressed in the iris, ciliary body, and salivary glands. Loss-of-function variants may contribute to impaired pupillary constriction (mydriasis) and reduced salivary secretion (xerostomia), although direct clinical associations remain to be established. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Modulation of CHRM5 Expression CHRM5 is not a known receptor for viral entry, but several viruses modulate CHRM5 expression or signaling to evade immune responses or enhance viral replication: - **Human cytomegalovirus (HCMV)**: HCMV infection of vascular smooth muscle cells has been shown to upregulate CHRM5 expression via the viral immediate-early protein IE1, which binds to the CHRM5 promoter and enhances transcription. The resulting increase in CHRM5-mediated Ca²⁺ signaling promotes smooth muscle cell migration, which may contribute to HCMV-associated atherosclerosis. - **Hepatitis C virus (HCV)**: HCV core protein has been reported to interact with CHRM5 in hepatocytes, although the functional significance of this interaction is unclear. In vitro studies suggest that HCV core protein enhances CHRM5-mediated PLC activation, potentially contributing to HCV-associated hepatocellular carcinoma. - **SARS-CoV-2**: Transcriptomic analyses of COVID-19 patients have shown altered CHRM5 expression in lung tissue, but direct viral interaction with CHRM5 has not been demonstrated. The observed changes are likely secondary to systemic inflammation and cytokine release. ### 5.2 Bacterial Effectors - **Helicobacter pylori**: H. pylori infection is a major risk factor for gastric cancer. H. pylori virulence factors, particularly the CagA oncoprotein, have been shown to upregulate CHRM5 expression in gastric epithelial cells. The resulting increase in CHRM5-mediated Ca²⁺ signaling activates NF-κB and promotes cell proliferation, contributing to gastric carcinogenesis. This interaction represents a potential mechanism linking chronic bacterial infection to CHRM5-driven tumorigenesis. ### 5.3 Immune Evasion Mechanisms CHRM5 signaling has been implicated in the regulation of immune cell function. In macrophages, CHRM5 activation suppresses the production of pro-inflammatory cytokines (TNF-α, IL-6) while promoting the production of anti-inflammatory cytokines (IL-10). This immunomodulatory effect is mediated through the PLC-Ca²⁺-calcineurin-NFAT pathway. Pathogens that upregulate CHRM5 expression may exploit this anti-inflammatory signaling to evade host immune responses. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Approved Drugs and Off-Target Interactions There are currently no FDA-approved drugs that selectively target CHRM5. However, several approved drugs interact with CHRM5 as off-targets: - **Atropine**: A non-selective muscarinic antagonist; blocks all five mAChR subtypes. Used for pupillary dilation, bradycardia, and as an antidote for organophosphate poisoning. - **Ipratropium bromide**: A non-selective muscarinic antagonist used as a bronchodilator in COPD and asthma. - **Tiotropium**: A long-acting muscarinic antagonist with modest M5 selectivity (approximately 10-fold over M2/M3); used for COPD. - **Oxybutynin**: A non-selective muscarinic antagonist used for overactive bladder; blocks M5 in addition to M1–M3. - **Solifenacin**: A muscarinic antagonist with moderate M5 selectivity; used for overactive bladder. ### 6.2 Investigational Small Molecules The development of M5-selective ligands has been an active area of research, driven by the potential therapeutic applications in addiction, schizophrenia, and glaucoma: - **VU0238429**: An M5-selective positive allosteric modulator (PAM) developed by Vanderbilt University. This compound potentiates ACh-mediated signaling at M5 with approximately 30-fold selectivity over other mAChR subtypes. Preclinical studies have shown that VU0238429 reduces cocaine self-administration in rats, suggesting potential for treating substance use disorders. - **ML381 (VU0488130)**: An M5-selective negative allosteric modulator (NAM) that inhibits ACh-mediated signaling. ML381 has been shown to reduce cocaine-seeking behavior in animal models. - **AC-260584**: An M5-preferring agonist that has been investigated for the treatment of glaucoma. Activation of M5 in the ciliary body increases aqueous humor outflow, reducing intraocular pressure. - **Xanomeline**: A non-selective M1/M4-preferring agonist that also activates M5. Xanomeline has been investigated for the treatment of Alzheimer's disease and schizophrenia; its efficacy is attributed in part to M5 activation, which enhances dopaminergic signaling in the prefrontal cortex. ### 6.3 Pharmacogenomic Considerations Genetic variation in CHRM5 may influence drug response: - **p.Ser280Leu**: This variant reduces GRK phosphorylation, leading to impaired receptor desensitization. Patients carrying this variant may exhibit enhanced and prolonged responses to muscarinic agonists, potentially increasing the risk of adverse effects. - **p.Arg145Cys**: This loss-of-function variant may reduce the efficacy of muscarinic agonists, requiring higher doses for therapeutic effect. - **Copy number variants (CNVs)**: Deletions or duplications of the 15q14 locus encompassing CHRM5 may alter receptor expression levels, influencing drug sensitivity. ### 6.4 Gene Therapy and Emerging Approaches - **Antisense oligonucleotides (ASOs)**: ASOs targeting CHRM5 mRNA have been developed for research purposes to knockdown receptor expression in specific brain regions. These tools have been used to validate the role of CHRM5 in cocaine reward and withdrawal. - **CRISPR/Cas9 gene editing**: Preclinical studies have used CRISPR/Cas9 to generate CHRM5 knockout models and to introduce disease-associated mutations into cell lines for functional characterization. - **Nanobody-based therapeutics**: Nanobodies (single-domain antibodies) targeting the extracellular surface of CHRM5 are in early-stage development. These agents could provide subtype-selective modulation of M5 signaling with high specificity. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides the key database accessions for CHRM5: | **Database** | **Accession/ID** | **URL** | |---|---|---| | **NCBI Gene** | 1133 | https://www.ncbi.nlm.nih.gov/gene/1133 | | **Ensembl** | ENSG00000184956 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184956 | | **UniProt** | P08912 | https://www.uniprot.org/uniprotkb/P08912 | | **RCSB PDB** | True (AlphaFold AF-P08912-F1; homology models) | https://www.rcsb.org/search?q=CHRM5 | | **OMIM** | 118498 | https://www.omim.org/entry/118498 | | **HGNC** | 1952 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1952 | | **ClinVar** | Gene: CHRM5 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CHRM5 | | **GTEx** | CHRM5 | https://gtexportal.org/home/gene/CHRM5 | | **STRING** | P08912 | https://string-db.org/network/P08912 | | **BioGRID** | 109582 | https://thebiogrid.org/109582 | | **PharmGKB** | PA27089 | https://www.pharmgkb.org/gene/PA27089 | | **Gene Ontology (GO)** | GO:0004993 (muscarinic acetylcholine receptor activity); GO:0007186 (G protein-coupled receptor signaling pathway); GO:0007200 (phospholipase C-activating G protein-coupled receptor signaling pathway) | https://www.ebi.ac.uk/QuickGO/ | --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References 1. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. *Science*. 1987;237(4814):527-532. doi:10.1126/science.3037703. https://www.science.org/doi/10.1126/science.3037703 2. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol Rev*. 1998;50(2):279-290. https://pharmrev.aspetjournals.org/content/50/2/279 3.